Gallium-68 NOTA AE105

Drug Profile

Gallium-68 NOTA AE105

Alternative Names: 68Ga NOTA AE105; 68Ga-NOTA-Asp-Cha-Phe-Ser-Arg-Tyr-Leu-Trp-Ser; CS 001

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Curasight
  • Developer Curasight; Rigshospitalet
  • Class Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Glioblastoma; Head and neck cancer; Mesothelioma; Neuroendocrine tumours; Non-small cell lung cancer; Oropharyngeal cancer; Prostate cancer

Most Recent Events

  • 13 Sep 2017 Rigshospitalet plans a phase II trial for Neuroendocrine tumours(Diagnosis) (NCT03278275)
  • 31 Mar 2017 Curasight completes a phase II trial in Breast cancer (Diagnosis) in Denmark (IV) (NCT02681640)
  • 19 Oct 2016 Phase-II clinical trials in Head and neck cancer (Diagnosis) in Denmark (IV) (EudraCT2016-002082-65)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top